Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- type II diabetes patients, female with non child-bearing potential
- Subjects with T2DM diagnosis for at least one year, treated with insulin alone or insulin in combination with other anti-diabetic drugs. Subjects must have been treated with insulin the last 3 months prior to enrolment (screening)
- HbA1c <11% at enrolment (screening) (HbA1c value according to international Diabetes Control and Complications Trial [DCCT] standard).
- FPG in the range of 7.0 to 13.0 mmol/L (126 to 234 mg/dL)
Exclusion Criteria:
- History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
- Use of glitazones, warfarin, amiodarone within 3 months prior to enrolment (screening) and use of potent CYP450 inhibitors, eg, ketoconazole and macrolide antibiotics within 14 days before randomisation.
- Any clinically significant abnormality identified on physical examination, laboratory tests or ECG, which in the judgment of the investigator would compromise the patients' safety or successful participation in the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily.
Subjects will thereafter be treated with this dose twice daily for another 24 days
|
Tolerable dose given twice daily
|
|
Placebo Comparator: 2
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily.
Subjects will thereafter be treated with this dose twice daily for another 24 days
|
Tolerable dose given twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systolic Blood Pressure, Change From Baseline to End of Treatment
Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
|
|
Diastolic Blood Pressure, Change From Baseline to End of Treatment
Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
|
|
Pulse, Change From Baseline to End of Treatment
Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
|
|
|
Weight, Change From Baseline to End of Treatment
Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment
|
Baseline is the day before first dose, end of treatment is last day of treatment
|
|
|
Clinically Relevant Change of Laboratory Variables
Time Frame: Measured regularly from day before first dose to day after last dose
|
Number of participants with clinically relevant change of laboratory variables (clinical chemistry, haematology and urinalysis parameters
|
Measured regularly from day before first dose to day after last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656
Time Frame: Measured last day of treatment
|
Dose-adjusted to a total daily dose of 100 mg due to titrated doses
|
Measured last day of treatment
|
|
Maximum Plasma Concentration of AZD1656
Time Frame: Measured following the morning dose last day of treatment
|
Dose-adjusted to a morning dose of 50 mg due to titrated doses
|
Measured following the morning dose last day of treatment
|
|
Time to Reach Maximum Plasma Concentration of AZD1656
Time Frame: Measured last day of treatment
|
Measured last day of treatment
|
|
|
Terminal Elimination Half-life of AZD1656
Time Frame: Measured following the evening dose last day of treatment
|
Measured following the evening dose last day of treatment
|
|
|
Apparent Oral Clearance of AZD1656
Time Frame: Measured last day of treatment
|
Measured last day of treatment
|
|
|
P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment
Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment
|
Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate.
Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Changes in percent have been obtained by subtraction by 100.
|
Baseline is the day before first dose, end of treatment is last day of treatment
|
|
S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment
Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment
|
Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate.
Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Changes in percent have been obtained by subtraction by 100
|
Baseline is the day before first dose, end of treatment is last day of treatment
|
|
S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment
Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment
|
Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate.
Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Changes in percent have been obtained by subtraction by 100.
|
Baseline is the day before first dose, end of treatment is last day of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Klas Malmberg, MD, PhD, Prof., AstraZeneca R&D Mölndal
- Principal Investigator: Marcus Hompesch, MD, Profil Institut for Clinical Research Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D1020C00020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.